The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.
The researchers have used nCounter, an FDA-cleared platform from NanoString Technologies, to develop their gene expression assay for subtype classification.
The company is seeing increasing interest in its GeoMx platform with numerous studies from early users presented last month at AACR.
The company reported total revenues of $27.7 million, with growth in its consumables business but a drop in instrument revenues from the prior year's first quarter.
The index, which underperformed the Dow Jones and the Nasdaq, fell nearly 3 percent in April.
Under the agreement, the companies will create a workflow integrating NanoString's GeoMx Digital Spatial Profiling instrument with Leica's Bond RX autostainer.
Under the agreement, Abcam will create custom panels for NanoString's GeoMx DSP platform from its collection of 6,000-plus recombinant monoclonal antibodies.
The planned product would combine RNA assays for NanoString's GeoMx digital spatial profiling instrument with Bio-Techne's RNAscope imaging reagents.
The company said it will offer 4.5 million shares for $23 per share and intends to use the net proceeds for working capital and general corporate purposes.
The company said it will offer 2.5 million shares, while stockholder Clarus Lifesciences will sell another 2 million shares in the offering.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.